乙基1-吡啶-3-基-2,3,4,9-四氢-1H-β-咔啉-3-羧酸酯 | 119377-08-1

• 分子结构分类: 有机化合物 - 生物碱及其衍生物 - 哈马拉生物碱
• 中文名称: 乙基1-吡啶-3-基-2,3,4,9-四氢-1H-β-咔啉-3-羧酸酯
• 英文名称: Ethyl 1,2,3,4-tetrahydro-1-(3-pyridyl)-9H-pyrido-[3,4-b]indole-3-carboxylate
• 英文别名: Ethyl 1-(3-pyridinyl)-2,3,4,9-tetrahydro-1H-pyrido(3,4-b)indole-3-carboxylate；ethyl 1-pyridin-3-yl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole-3-carboxylate
• CAS: 119377-08-1
• 化学式: C₁₉H₁₉N₃O₂
• 分子量: 321.379
• InChiKey: ZFLNWCZNOYUZFZ-UHFFFAOYSA-N

物化性质

• 沸点：
  518.0±50.0 °C(Predicted)
• 密度：
  1.254±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  24
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.26
• 拓扑面积：
  67
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  乙基1-吡啶-3-基-2,3,4,9-四氢-1H-β-咔啉-3-羧酸酯 在 potassium permanganate 作用下， 以 四氢呋喃 为溶剂， 反应 0.5h， 生成 1-吡啶-3-基-9H-吡啶并[3,4-b]吲哚-3-羧酸乙酯
  参考文献：
  名称：

  Cegla, M.; Duszynska, Beata; Misztal, S., Pharmazie, 1988, vol. 43, # 7, p. 510

  摘要：

  DOI：
• 作为产物：
  描述：

  3-吡啶甲醛 、 DL-tryptophan ethyl ester 在 对甲苯磺酸 作用下， 以 甲苯 为溶剂， 反应 8.0h， 生成 乙基1-吡啶-3-基-2,3,4,9-四氢-1H-β-咔啉-3-羧酸酯
  参考文献：
  名称：

  Cegla, M.; Duszynska, Beata; Misztal, S., Pharmazie, 1988, vol. 43, # 7, p. 510

  摘要：

  DOI：

文献信息

• Tetracyclic derivatives, process of preparation and use
  申请人：ICOS Corporation

  公开号：US20020119976A1

  公开（公告）日：2002-08-29

  A compound of formula (I) 1 and salts and solvates thereof, in which: R o represents hydrogen, halogen or C 1-6 alkyl; R 1 represents hydrogen, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, halo C 1-6 alkyl, C 3-8 cycloalkyl, C 3-8 cycloalkyl C 1-3 alkyl, arylC 1-3 alkyl or heteroaryl C 1-3 alkyl; R 2 represents an optionally substituted monocyclic aromatic ring selected from benzene, thiophene, furan and pyridine or an optionally substituted bicyclic ring 2 attached to the rest of the molecule via one of the benzene ring carbon atoms and wherein the fused ring A is a 5- or 6-membered ring which may be saturated or partially or fully unsaturated and comprises carbon atoms and optionally one or two heteroatoms selected from oxygen, sulphur and nitrogen; and R 3 represents hydrogen or C 1-3 alkyl, or R 1 and R 3 together represent a 3- or 4-membered alkyl or alkenyl chain. A compound of formula (I) is a potent and'selective inhibitor of cyclic guanosine 3′, 5′-monophosphate specific phosphodiesterase (CGMP specific PDE) having a utility in a variety of therapeutic areas where such inhibition is beneficial, including the treatment of cardiovascular disorders.

  式(I)1的化合物及其盐和溶剂化物，其中：R代表氢，卤素或C1-6烷基；R1代表氢，C1-6烷基，C2-6烯基，C2-6炔基，卤代C1-6烷基，C3-8环烷基，C3-8环烷基C1-3烷基，芳基C1-3烷基或杂环芳基C1-3烷基；R2代表一个可选的取代的单环芳香环，选择自苯，噻吩，呋喃和吡啶或一个可选的取代的二环2，通过苯环碳原子之一连接到分子的其余部分，其中融合的环A是一个5-或6-成员环，可以是饱和的或部分或完全不饱和的，并包括碳原子和可选的一个或两个异原子，选择自氧，硫和氮；R3代表氢或C1-3烷基，或R1和R3一起代表一个3-或4-成员烷基或烯基链。式(I)的化合物是环鸟苷3'，5'-单磷酸特异性磷酸二酯酶（CGMP特异性PDE）的有效和选择性抑制剂，具有在多种治疗领域中抑制有益的功效，包括心血管疾病的治疗。
• Method of inhibiting neoplastic cells with tetracyclic pyrido[3,4-B] indole derivatives
  申请人：——

  公开号：US20020035111A1

  公开（公告）日：2002-03-21

  A method for inhibiting neoplasia, particularly cancerous and precancerous lesions by exposing the affected cells to pyrido[3,4b]indoles.

  一种通过将受影响的细胞暴露于吡啶并［3,4b］吲哚来抑制肿瘤，特别是癌症和癌前病变的方法。
• BIS-B-CARBOLINE COMPOUND AND PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USE THEREOF
  申请人：XINJIANG HUASHIDAN PHAR MACEUTICAL RESEARCH CO., LTD

  公开号：US20160039845A1

  公开（公告）日：2016-02-11

  Disclosed in the present invention are a bis-β-carboline compound and a preparation method, a pharmaceutical composition and the use thereof. In particular, the bis-β-carboline compound and a pharmaceutical salt thereof are described as general formula I, and the bis-β-carboline compound is prepared through the condensation of β-carboline intermediate and dihaloalkane. Also disclosed in the present invention are a pharmaceutical composition comprising an effective dose of the bis-β-carboline compound as shown in formula I and a pharmaceutically acceptable carrier, and the use of the bis-β-carboline compound in preparing drugs resistant to tumours such as melanoma, stomach cancer, lung cancer, breast cancer, kidney cancer, liver cancer, oral epidermoid carcinoma, cervical cancer, ovarian cancer, pancreatic cancer, prostate cancer, and colon cancer.

  本发明公开了一种双β-咔唑化合物及其制备方法、药物组合物及其用途。其中，描述了双β-咔唑化合物及其药物盐的一般式I，双β-咔唑化合物是通过β-咔唑中间体和二卤代烷的缩合反应制备而成。本发明还公开了一种药物组合物，包括一定剂量的公式I所示的双β-咔唑化合物和药学上可接受的载体，并且公开了将双β-咔唑化合物用于制备对肿瘤具有抗药性的药物，如黑色素瘤、胃癌、肺癌、乳腺癌、肾癌、肝癌、口腔表皮癌、宫颈癌、卵巢癌、胰腺癌、前列腺癌和结肠癌。
• (6R,12aR)-2,3,6,7,12,12a-hexahydro-2-methyl-6-(3,4-methylenedioxyphenyl)-pyrazino[2',1':6,1]pyrido[3,4-b]indole-1,4-dione for the treatment of benign prostatic hypertrophy
  申请人：ICOS Corporation

  公开号：EP2036560A1

  公开（公告）日：2009-03-18

  Compound (6R,12aR)-2,3,6,7,12,12a-hexahydro-2-methyl-6-(3,4-methylenedioxyphenyl)-pyrazino [2', 1':6,1]pyrido[3,4-b]indcle-1,4-dione for the treatment of benign prostatic hypertrophy.

  用于治疗良性前列腺肥大的化合物 (6R,12aR)-2,3,6,7,12,12a-六氢-2-甲基-6-(3,4-亚甲基二氧苯基)-吡嗪并[2', 1':6,1]pyrido[3,4-b]indcle-1,4- 二酮。
• Tetracyclic cyclic gmp-specific phosphodiesterase inhibitors for the treatment of benign prostatic hypertrophy
  申请人：ICOS Corporation

  公开号：EP2327408A1

  公开（公告）日：2011-06-01

  A compound of formula (1) and salts and solvates thereof, in which: R0 represents hydrogen, halogen, or Cl-6alkyl; R1 represents hydrogen, C1-6-alkyl, C2-6alkenyl, C2-6alkynyl, haloC1-6alkyl, C3-8cycloalkyl, C3-8cyloalkylcl-3alkyl, arylC1-3alkyl, or heteroarylcl-3alkyl; R2 represents an optionally substituted monocyclic aromatic ring selected from benzene, thiophene, furan, and pyridine, or an optionally substituted bicyclic ring (a) attached to the rest of the molecule via one of the benzene ring carbon atoms, and wherein the fused ring (A) is a 5- or 6-membered ring which may be saturated or partially or fully unsaturated, and comprises carbon atoms and optionally one or two heteroatoms selected from oxygen, sulphur, and nitrogen; and R3 represents hydrogen or Cl-alkyl, or R1 and R3 together represent a 3- or 4-membered alkyl or alkenyl chain. A compound of formula (I) is a potent and selective inhibitor of cyclic guanosine 3', 5'-monophosphate specific phosphodiesterase (cGMP specific PDE) having a utility in a variety of therapeutic areas where such inhibition is beneficial, including the treatment of benign prostatic hypertrophy.

  式(1)化合物及其盐和溶剂，其中：R0 代表氢、卤素或 Cl-6 烷基；R1 代表氢、C1-6-烷基、C2-6-烯基、C2-6-炔基、卤代 C1-6 烷基、C3-8-环烷基、C3-8-环烷基环 3 烷基、芳基 C1-3 烷基或杂芳基环 3 烷基；R2 代表任选取代的单环芳香环，选自苯、噻吩、呋喃和吡啶，或任选取代的双环 (a)，通过其中一个苯环碳原子连接到分子的其余部分，其中融合环 (A) 是 5 或 6 元环，可以是饱和环或部分或完全不饱和环，包括碳原子和任选选自氧、硫和氮的一个或两个杂原子；R3 代表氢或 Cl-烷基，或 R1 和 R3 共同代表 3 或 4 元烷基或烯基链。式（I）化合物是环鸟苷-3'，5'-单磷酸特异性磷酸二酯酶（cGMP 特异性 PDE）的强效选择性抑制剂，可用于多种治疗领域，包括治疗良性前列腺肥大。